Literature DB >> 11104214

Internal globus pallidotomy in dystonia secondary to Huntington's disease.

E Cubo1, K M Shannon, R D Penn, J S Kroin.   

Abstract

INTRODUCTION AND
METHOD: The prototypic motor feature of Huntington's disease (HD) is chorea, but parkinsonism and involuntary movements such as dystonia and myoclonus can also be present. Pallidotomy has been shown to be an effective treatment for medically refractory Parkinson's disease (PD). We performed bilateral microelectrode guided-stereotactic pallidotomies targeted at globus pallidum internus (GPi) to treat a 13-year-old patient diagnosed with Westphal variant of HD with intractable generalized dystonia and parkinsonism.
RESULTS: Intraoperative microelectrode recordings of GPi cells showed a relatively low firing rate, 29 +/- 14 Hz, with most neurons showing pauses. Acutely, after surgery, limb dystonia mildly improved but trunk dystonia persisted. Postoperative follow up 3 months later showed minimal clinical improvement in dystonic features with marked worsening of spasticity.
CONCLUSION: In our case, bilateral pallidotomy produced modest palliative functional improvement in dystonic features. Cellular firing patterns were markedly different than in PD and were similar to those found in dystonia.

Entities:  

Mesh:

Year:  2000        PMID: 11104214     DOI: 10.1002/1531-8257(200011)15:6<1248::aid-mds1029>3.0.co;2-q

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  10 in total

Review 1.  Experimental surgical therapies for Huntington's disease.

Authors:  Jelle Demeestere; Wim Vandenberghe
Journal:  CNS Neurosci Ther       Date:  2010-12-28       Impact factor: 5.243

2.  Pallidal neuronal discharge in Huntington's disease: support for selective loss of striatal cells originating the indirect pathway.

Authors:  Philip A Starr; Gail A Kang; Susan Heath; Shoichi Shimamoto; Robert S Turner
Journal:  Exp Neurol       Date:  2008-02-14       Impact factor: 5.330

Review 3.  Reassessing models of basal ganglia function and dysfunction.

Authors:  Alexandra B Nelson; Anatol C Kreitzer
Journal:  Annu Rev Neurosci       Date:  2014       Impact factor: 12.449

4.  Firing rates of pallidal neurons are similar in Huntington's and Parkinson's disease patients.

Authors:  Joyce K H Tang; Elena Moro; Andres M Lozano; Anthony E Lang; William D Hutchison; Neil Mahant; Jonathan O Dostrovsky
Journal:  Exp Brain Res       Date:  2005-08-05       Impact factor: 1.972

Review 5.  Huntington's Disease-Update on Treatments.

Authors:  Kara J Wyant; Andrew J Ridder; Praveen Dayalu
Journal:  Curr Neurol Neurosci Rep       Date:  2017-04       Impact factor: 5.081

6.  Deep brain stimulation of the internal pallidum in Huntington's disease patients: clinical outcome and neuronal firing patterns.

Authors:  Cécile Delorme; Alister Rogers; Brian Lau; Hélène Francisque; Marie-Laure Welter; Sara Fernandez Vidal; Jérôme Yelnik; Alexandra Durr; David Grabli; Carine Karachi
Journal:  J Neurol       Date:  2015-11-14       Impact factor: 4.849

Review 7.  What happened to posteroventral pallidotomy for Parkinson's disease and dystonia?

Authors:  Robert E Gross
Journal:  Neurotherapeutics       Date:  2008-04       Impact factor: 7.620

Review 8.  Deep Brain Stimulation in Huntington's Disease-Preliminary Evidence on Pathophysiology, Efficacy and Safety.

Authors:  Lars Wojtecki; Stefan Jun Groiss; Christian Johannes Hartmann; Saskia Elben; Sonja Omlor; Alfons Schnitzler; Jan Vesper
Journal:  Brain Sci       Date:  2016-08-30

9.  Rescue GPi-DBS for a Stroke-associated Hemiballism in a Patient with STN-DBS.

Authors:  Genko Oyama; Nicholas Maling; Amanda Avila-Thompson; Pam R Zeilman; Kelly D Foote; Irene A Malaty; Ramon L Rodriguez; Michael S Okun
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2014-02-04

Review 10.  Bilateral Pallidotomy for Dystonia: A Systematic Review.

Authors:  Liesanne M Centen; D L Marinus Oterdoom; Marina A J Tijssen; Ivon Lesman-Leegte; Martje E van Egmond; J Marc C van Dijk
Journal:  Mov Disord       Date:  2020-11-20       Impact factor: 10.338

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.